The global point-of-care infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025, according to a new report by Grand View Research, Inc. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.
Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in this market through to 2025.
For instance, development of a new ‘lab-on-a-disc’ technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
HIV POC is estimated to account for the largest share owing to the rising incidence of this disease
Advances in the bio sensing technology for the early detection with sensitivity is expected to fuel revenue generation in the coming years
Moreover, companies are engaged in embracing a quality management approach for the introduction of novel tests for HIV diagnosis
TB and drug resistant TB is anticipated to witness lucrative demand in the coming years as a result of rise in the incidence rate of drug resistance TB
Demand for the development of inexpensive, rapid, simple, and accurate tests that are able to detect multiple biomarkers simultaneously is expected to boost progress
Implementation of fully or partially integrated nano/microscale technologies in developing DR-TB diagnostic devices is anticipated to fuel progress in the segment
Clinics accounted for the largest revenue share owing to the higher usage of rapid testing kits in clinics
North America dominates the space with adequate administration support, well-established healthcare framework, and extensive research & technology upgradation
Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support
The major players in the sector include Siemens Healthineers, Trivitron Healthcare, F. Hoffmann-La Roche Ltd, Alere, Quest Diagnostics, Inc, BD & Company, Chembio Diagnostics Inc,Trinity Biotech, Cardinal Health,Bio-Rad Labs Inc.,bioMérieux SA, Thermo Fisher Scientific Inc, Sight Diagnostics Ltd.,Gene POC, Ortho-Clinical Diagnostics, and OJ-Bio Ltd.
Companies are entering into collaborations with academic institutions, private, and public entities to enhance their market share
Grand View Research has segmented the point-of-care infectious disease diagnostics/testing market on the basis of disease, end-use, and region:
Disease Outlook (Revenue, USD Million; 2014-2025)
Clostridium difficile POC
Pneumonia or Streptococcus associated infections
Respiratory syncytial virus (RSV) POC
TB and drug-resistant TB POC
HSV (Herpes Simplex Virus) POC
Other infectious disease POC
End-Use Outlook (Revenue, USD Million; 2014-2025)
Assisted Living Healthcare Facilities
Regional Outlook (Revenue, USD Million; 2014-2025)
Middle East and Africa (MEA)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.